BYSI unit SEED Therapeutics gets FDA orphan drug designation for ST-01156
BeyondSpring’s subsidiary SEED Therapeutics receives FDA orphan drug designation for ST-01156, a small molecule degrader of RNA-binding motif protein 39, for neuroblastoma.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.